Introduction Pyridoxal 5’-phosphate (PLP), the biologically active form of vitamin B6 is involved in 4% of cellular enzymatic activities and its deficiency is responsible for or contributes to several human diseases. The study of underlying mechanisms is still in its infancy and requires suitable model organisms. In Drosophila the deficiency of vitamin B6 produces chromosome aberrations and hallmarks of human diseases including diabetes and cancer. However, the effects of vitamin B6 deficiency have never been examined at a metabolic level. Objectives This study evaluates the metabolic changes in vitamin B6 deficient Drosophila larvae with the aim of validating flies as a suitable model for diseases associated to vitamin B6 deficiency Methods To induce vitamin B6 deficiency we fed Drosophila wild type larvae with 4-deoxypyridoxine (4DP), a PLP antagonist. By HPLC analysis we verified that the 4DP treatment was effective in inducing vitamin B6 deficiency. Using an NMR-based metabolomic approach we compared the metabolites in larval extracts from untreated and 4DP-fed larvae. Results The NMR spectra analysis identified quantitative differences for sixteen metabolites out of forty, including branched chain and aromatic amino acids, glucose, and lipids, thus revealing interesting possible associations with the phenotypes showed by vitamin B6 deficient flies Conclusions Our results validate Drosophila as a suitable model to study in depth the molecular mechanisms underlying human diseases associated with vitamin B6 deficiency and confirmed that 4DP treatment is effective in inducing vitamin B6 deficiency.
Vitamin B6 deficiency produces metabolic alterations in Drosophila / Tesoriere, Giulia; Pilesi, Eleonora; DE ROSA, Michele; Giampaoli, Ottavia; Patriarca, Adriano; Spagnoli, Mariangela; Chiocciolini, Federica; Tramonti, Angela; Contestabile, Roberto; Sciubba, Fabio; Verni, Fiammetta. - In: METABOLOMICS. - ISSN 1573-3882. - 21:(2025). [10.1007/s11306-025-02236-0]
Vitamin B6 deficiency produces metabolic alterations in Drosophila
Giulia Tesoriere;Eleonora Pilesi;Michele De Rosa;Ottavia Giampaoli;Adriano Patriarca;Mariangela Spagnoli;Federica Chiocciolini;Angela Tramonti;Roberto Contestabile;Fabio Sciubba;Fiammetta Verni
Ultimo
Conceptualization
2025
Abstract
Introduction Pyridoxal 5’-phosphate (PLP), the biologically active form of vitamin B6 is involved in 4% of cellular enzymatic activities and its deficiency is responsible for or contributes to several human diseases. The study of underlying mechanisms is still in its infancy and requires suitable model organisms. In Drosophila the deficiency of vitamin B6 produces chromosome aberrations and hallmarks of human diseases including diabetes and cancer. However, the effects of vitamin B6 deficiency have never been examined at a metabolic level. Objectives This study evaluates the metabolic changes in vitamin B6 deficient Drosophila larvae with the aim of validating flies as a suitable model for diseases associated to vitamin B6 deficiency Methods To induce vitamin B6 deficiency we fed Drosophila wild type larvae with 4-deoxypyridoxine (4DP), a PLP antagonist. By HPLC analysis we verified that the 4DP treatment was effective in inducing vitamin B6 deficiency. Using an NMR-based metabolomic approach we compared the metabolites in larval extracts from untreated and 4DP-fed larvae. Results The NMR spectra analysis identified quantitative differences for sixteen metabolites out of forty, including branched chain and aromatic amino acids, glucose, and lipids, thus revealing interesting possible associations with the phenotypes showed by vitamin B6 deficient flies Conclusions Our results validate Drosophila as a suitable model to study in depth the molecular mechanisms underlying human diseases associated with vitamin B6 deficiency and confirmed that 4DP treatment is effective in inducing vitamin B6 deficiency.| File | Dimensione | Formato | |
|---|---|---|---|
|
Tesoriere_Vitamin-B6-deficiency_2025.pdf
accesso aperto
Note: Articolo in rivista
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Creative commons
Dimensione
1.56 MB
Formato
Adobe PDF
|
1.56 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


